Module 2
Module 2. Drugs influence internal organs, blood system, human exchange and immunity. Chemotherapeutic drugs.
|Control of theoretical knowledge |Control of practical skills |
|Topic 17 |
|Classification of cardiac glycosides in origin and physico-chemical |Correction of medical prescriptions for cardiac glycosides. |
|properties. |Consultation on safe therapy by cardiac glycosides. Choose from |
|The mechanism of action of cardiac glycosides, their pharmacodynamics. |following the collection of cardiac glycosides: digitalis, |
|Dependence of pharmacokinetics of cardiac glycosides from their |strophanthus, lilies and not glycoside cardiotonic drugs. |
|physico-chemical properties. Influence the pharmacokinetics of cardiac |Among the listed drugs containing macro-and micronutrients (sodium, |
|glycosides on their pharmacodynamics and indications for use. |calcium, potassium, magnesium), choose those that are prescribed for |
|The logical connection between the adverse effects of cardiac glycosides |the prevention of adverse effects of cardiac glycosides. |
|and contraindications to their use. Features of cardiac glycosides |Recommendations to patients on the rules of rational use of cardiac |
|dosage, types of digitalization. Cardiac glycosides intoxication, the |glycosides. |
|principles of prevention and treatment. |Inform the doctor on interchangeability of cardiac glycosides based |
|Classification and main indications for using no glycoside cardiotonics. |on the availability of the pharmaceutical market of original and |
|Classification and features of antiarrhythmic agents depending on the |generic drugs in this group. |
|mechanism of action and the type of arrhythmia. |Correction of medical prescriptions for antiarrhythmic drugs. |
|Topic 18 |
|Classification of hypotensive drugs. Pharmacological characteristic |Correction of medical prescriptions for antihypertensives of the |
|hypotensive drugs of the central action. The logical connection between |central action. |
|the side effects hypotensive drugs of the central action and |Consultation on differences of the use of hypotensive drugs of the |
|contraindications to their use. |central action (depending on the patient, the nature of side |
|Pharmacological characteristics of (-adrenoblockers as hypotensive drugs.|effects); counseling the patient about the rules of rational use of |
|The logical relationship between pharmacological effects and indications |these drugs. |
|for use (-adrenoblockers in essential hypertension. Differences in the |Correction of medical prescriptions for (-adrenoblockers and |
|use of short-form and retard-form of (1-adrenoblockers in essential |(-adrenoblockers. |
|hypertension. |Consultation on the interchangeability of (1-adrenoblockers, the |
|Features of pharmacodynamics and indications for use of cardioselective |availability of new drugs in the pharmaceutical market. |
|and not cardioselective (-adrenoblockers. |Recommendations a doctor on the choice of (-adrenoblockers for |
|The logical connection between the side effects of (1, (-adrenoblockers |pharmacotherapy of essential hypertension based pharmacokinetic and |
|and contraindications to their use. Pharmacological characteristics of |pharmacodynamic properties of drugs in this group, as well as on the |
|sympatholytics. The logical connection between side effects of |benefits of (-adrenoblockers of new generation to traditional drugs. |
|sympatholytics and contraindications to their use. |Consultation of a doctor and a patient to prevent side effects that |
|Pharmacological justification for the use of ganglioplegics as |occur with prolonged use of traditional (-adrenoblockers. |
|antihypertensives. Features of pharmacodynamics of ganglioplegics |Correction of medical prescriptions for SCCB. |
|depending on their pharmacokinetics. The logical connection between side |Recommendation a doctor regarding interchangeability of SCCB |
|effects of ganglioplegics and contraindications to their use. |including pharmacodynamics, pharmacokinetics, medicinal forms, side |
|Classification of slow calcium channel blockers (SCCB) in chemical |effects, international and trade names of drugs. Advantages and |
|structure, pharmacokinetic characteristics and generations. Mechanism of |disadvantages of different medicinal forms of SCCB. |
|the hypotensive action of SCCB. Features of pharmacodynamics and |Correction of medical prescriptions for ACE inhibitors and |
|indications for use of SCCB depending on the chemical structure and |angiotensin II receptor antagonists. |
|dosage form. Comparison of new generation of SCCB compared to first |Recommendations the doctor regarding the dosage of ACE inhibitors, |
|generation (pharmacokinetic and pharmacodynamic properties, etc.). The |their interchangeability, warning of possible side effects, the |
|logical connection between the major side effects of SCCB and |availability of new brands and generic drugs in the pharmaceutical |
|contraindications to their use. |market. |
|Classification of ACE inhibitors (ACEI) in chemical structure and |Consultation the patient on rational use of ACE inhibitors for the |
|pharmacokinetic characteristics. |prevention of possible complications. |
|Pharmacological characteristics of ACE. The logical connection between |Choose from a collection of vasodilators and spasmolytics of |
|the side effects of ACE inhibitors and contraindications to their use. |myotropic action for the treatment of hypertensive crisis. |
|Angiotensin II receptor antagonists as an alternative to ACE inhibitors |Consultation on the rational use of of antihypertensive drugs of |
|(mechanism of hypotensive action, especially pharmacodynamics, unlike |different groups. |
|ACE). |Correction of medical prescriptions for anti-sclerotic drugs. |
|Peripheral vasodilators and spasmolytics of myotropic action, their |Consultation the patient on rational use of antisclerotic means to |
|mechanism of hypotensive action, pharmacodynamics, indications. |prevent possible complications. |
|Groups of diuretics used in hypertension, features of their application. |Choose from a collection the drugs for the treatment of hypotension, |
|Combined antihypertensive drugs. Rational and irrational combinations of |collapse, shock and antisclerotic drugs. |
|antihypertensive drugs. Means used for the treatment of hypertensive | |
|crisis. | |
|Classification of antisclerotic funds. Mechanism of action and | |
|pharmacodynamics of statins, fibrates, bile acid sequestrants, nicotinic | |
|acid preparations, angioprotectors, essential phospholipids. | |
|The logical connection between the side effects of hypolipidemic drugs | |
|and contraindications to their use. Classification and pharmacological | |
|characteristics of that increase blood pressure. | |
|Topic 19 |
|Classification of of antianginal drugs. Classification of organic |Correction of medical prescriptions for organic nitrates. |
|nitrates in chemical structure and duration. Pharmacological |Consultation on the interchangeability of organic nitrates including |
|characteristics of of organic nitrates. Indications for use of organic |pharmacokinetics, dosage form, the patient's condition and |
|nitrates depending on the medicinal form and pharmacokinetics. |availability of brands and generic drugs in the pharmaceutical |
|Main pharmacokinetic differences of major groups of organic nitrates |market. |
|(glyceryl trinitrate, isosorbide dinitrat, isosorbide mononitrate). The |Recommendations a patient regarding conditions of rational use of |
|mechanism of tolerance to nitrates and ways of correction. |organic nitrates. |
|The logical connection between the adverse effects of organic nitrates |Recommendations doctor about choosing preparations to overcome |
|and contraindications to their use. The mechanism of antianginal action |tolerance that occurs to organic nitrates. |
|(-adrenoblockers. |Choose from a collection of modern medicines (-adrenoblockers to |
|The mechanism of antianginal action SCCB. Pharmacological features SCCB |assign patients with coronary artery disease. |
|depending on the medicinal form of the drug and its chemical structure. |Correction of medical prescriptions for SCCB. |
|Antianginal agents of reflex action, mechanism of action, |Consultation of doctor and patient on modern medicinal forms of |
|pharmacodynamics. Pharmacological characteristics of new antianginal |antianginal agents for the treatment of angina pectoris and the |
|drugs - selective inhibitor f-channels of sinus node (ivabradyn). |prevention of these attacks. |
|Classification and pharmacological characteristic of cardioprotectors, |Choose from a collection of medicines cardioprotectors, antioxidants |
|antioxidants. |of direct and indirect action. Recommendation to a doctor for the |
|Classification and pharmacological characteristics of drugs that improve |rational selection of medicines containing vitamins and minerals to |
|cerebral blood flow: calcium channel blockers, derived of uterine horn, |assign patients with coronary artery disease. Correction of medical |
|Ginko Biloba preparations, and others. |prescriptions for drugs that improve cerebral circulation, |
|The logical relationship between side effects and contraindications to |cardioprotectors and antioxidants. Consultation of a doctor on the |
|the use of drugs that improve cerebral blood flow. |interchangeability of drugs that improve cerebral circulation. |
| |Recommendation a patient on rational acceptance of drugs that improve|
| |cerebral blood flow. |
|Topic 20 |
|The common definition of "anti-ulcer", "antacid" drugs, |Correction of prescriptions for drugs that are pouring into the |
|"gastroprotectors", "hepatoprotectors". |function of the gastrointestinal tract. |
|Classification and pharmacological characteristics of drugs that affect |Consultation a doctor on assortment of drugs that affect the |
|appetite, the secretory function of the stomach and pancreas. Comparison |secretory function of the stomach and pancreas, on the modern |
|of antisecretory drugs of different mechanism of action and antacids of |pharmaceutical market of interchangeability of drugs based on their |
|different generations. |"pharmacological face". |
|The pharmacological characteristics of drugs that affect the motility of |Informing patients about the conditions of rational use of drugs that|
|the gastrointestinal tract. The logical link between adverse effects and |stimulate appetite, antacids, antisecretory agents. Choose from a |
|contraindications to the use of drugs affecting the secretory and motor |collection of drugs the antacid drugs and their distribution for |
|functions of the gastrointestinal tract. |generations. |
|Classification and the pharmacological characteristic of |Consultation on the interchangeability of hepatoprotectors and |
|hepatoprotectors, choleretic agents. Comparison of hepatoprotectors of |choleretic drugs based on the presence of brands and generic drugs in|
|synthetic and plant origin. Classification and pharmacological |the pharmaceutical market. Choose from a collection of drugs |
|characterization of laxatives, anti-flatulence, and anti- diarrheal |laxatives of different mechanism of action. Patient consultation on |
|drugs. |rational use of laxatives, anti-flatulence, and anti-diarrheal |
| |drugs. |
|Topic 21 |
|The common definition of "diuretic" drugs. |Correction of medical prescriptions for diuretic and drugs for |
|Classification of diuretic drugs on the mechanism of action and origin. |treatment gout. Recommendation a doctor regarding the |
|The logical link between the pharmacological effects of diuretic drugs |interchangeability of diuretics with the peculiarities of their |
|and indications for their use. |mechanism of action and pharmacodynamics. Informing physicians for |
|Comparison of diuretic drugs according to their mechanisms of action and |efficient and safe use of diuretics combined with drugs other groups.|
|pharmacodynamic characteristics. The logical relationship between side | |
|effects and contraindications to the use of diuretic drugs. Features of |Consultation a patient on rational use of diuretic drugs. Choose from|
|the application of plant origin diuretics. |a collection of herbal remedies diuretics and hypoazotemic drugs. |
|Pharmacological characteristic of drugs for treatment of gout with |Consultation a doctor on assortment of modern drugs for treatment |
|different mechanism of action. |gout on the pharmaceutical market. |
|Classification of drugs that affect the myometrium. Definition of |Correction of medical prescriptions for drugs with uterotonic action.|
|"uterotonics". | |
|Classification and pharmacological characteristic of uterotonics. |Informing physicians of the presence on the pharmaceutical market of |
|Comparative characteristics of drugs with uterotonic action: oxytocin, |contemporary uterotonic drugs. |
|uterine horn and prostaglandins. The logical relationship between side |Counseling patients on rational use of uterotonics. |
|effects and contraindications uterotonics. |Choose from a collection the drugs of uterotrophic action, their |
|Definition of "tokolitics." Classification and pharmacological |distribution on uterotonics and tocolitics. |
|characteristic of modern tocolytic agents. Comparison of tokolitics |Correction of medical prescriptions for tocolytic drugs. |
|considering features of their mechanism of action. |Recommendation a doctor regarding the interchangeability of tocolytic|
|The risk / benefit of the use of tocolitics in various term of gestation.|drugs according their pharmacodynamics, side effects and presence in |
|Definition of "prostatoprotectors." Classification and pharmacological |the pharmaceutical market. Correction of medical prescriptions for |
|characteristic prostatoprotectors considering their origin and |prostatoprotectors. |
|composition (combination herbal medicinal products). |Consultation a doctor on the interchangeability of drugs, presence |
|Definition of " erectile dysfunction correctors." Classification and |for new prostatoprotectors on the pharmaceutical market. |
|pharmacological characteristics of erectile dysfunction correctors. Risk |Choose from a collection of erectile dysfunction correctors due to |
|/ benefit ratio of erectile dysfunction correctors use in patients taking|availability of brands and generic drugs in the pharmaceutical |
|nitrovasodilatators et other medicines. |market. |
| |Information for patients on the rational use of correctors of |
| |erectile dysfunction. |
| |
|Topic 22 |
|Classification of medicines that affect the clotting of blood and |Correction of medical prescriptions for anticoagulants, hemostatics, |
|haemopoiesis. |activators and inhibitors of fibrinolysis, antiplatelet agents. |
|Pharmacological characterization of anticoagulants. Comparative |Information for the doctor on the interchangeability of |
|pharmacological characteristics of low-molecular-weight heparin (LMWH) |anticoagulants based on their pharmacological properties. |
|with heparin; anticoagulants of direct and indirect action. |Choosing antidote in overdose of heparin. Information for doctors to |
|Pharmacological characterization of fibrinolytic agents. Classification |prevent the side effects associated with overdose of anticoagulants |
|and pharmacological characteristics of antiplatelet agents. Features of |of indirect action. Choose from a collection hemostatics drugs of |
|their use in cardiology, nephrology, ophthalmology, obstetrics. |plant origin. |
|Definition of "hemostatics." Classification and pharmacological |Correction of medical prescriptions for drugs that affect |
|characteristic of hemostatics. The logical relationship between |leucopoiesis and erythropoiesis. Consulting physicians regarding the |
|pharmacodynamics and indications for use of coagulants. |range of modern drugs that affect leucopoiesis for |
|Classification and pharmacological characteristics of drugs affecting |interchangeability. |
|leucopoiesis. |Inform a doctor about modern iron preparations and characteristics of|
|Classification and pharmacological characteristics of drugs that |their various dosage forms. Counseling patients on the terms of the |
|stimulate erythropoiesis. |rational use of iron supplements to prevent complications during |
|Classification and pharmacological characteristics of erythropoietin, |pharmacotherapy prepartamy iron. |
|iron, folic acid and cyanocobalamin. Comparison of two- and trivalent | |
|iron. Principles of rational combination of iron supplementation with | |
|vitamins, trace elements, laxatives. Pharmaceutical features of modern | |
|iron drugs. | |
|Topic 23 |
|Sources of hormones, their dosage, types of hormone therapy. |Correction of medical prescriptions for hormones of the hypothalamus,|
|Classification of hormones in chemical structure. Pharmacological |pituitary, thyroid, parathyroid glands, insulin, synthetic |
|characteristics of hormones of the hypothalamus, pituitary, pineal, |antidiabetic drugs. Consultation on the interchangeability of |
|thyroid drugs and parathyroid glands. Antihormonal drugs. Classification |hormones from the knowledge of the international nomenclature, trade |
|of insulin in origin and duration. |names, pharmacological properties, indications for use |
|Pharmacological characteristics of insulin. Features of insulin dosage |Recommendations for patients on the rational use of hormonal and |
|depending on the dosage form. Preparations for first aid in hyperglycemic|antihormonal drugs of different groups. Choice of drug collection |
|and hypoglycemic commas. Classification and pharmacological |antidiabetic drugs of different groups and different generations. |
|characteristic of synthetic oral antidiabetic drugs. Pharmacological |Patient information for rational use of antidiabetic drugs. |
|justification of the combined use of antidiabetic drugs of different | |
|groups. | |
|Topic 24 |
|Classification of steroid hormone drugs. Pharmacological characteristics |Correction of medical prescriptions for adrenal hormones. |
|of mineralocorticosteroids. |Consultation for physicians on interchange, the availability of new |
|Classification of glucocorticosteroids (GCS) for their origin, chemical |drugs from the group of corticosteroids on the pharmaceutical market.|
|structure, route of administration, type of pharmacological action. |Informing patients about side effects of corticosteroids and |
|The logical relationship between the pharmacological effects of |conditions of their rational use, especially during prolonged use. |
|corticosteroids and indications for their use, side effects and |Choose from a collection of drug preparations containing |
|contraindications to their use. |mineralocorticoids, corticosteroids and their antagonists. |
|Comparison of natural and synthetic origin GCS. Differences between |Pick up drugs according to a logical chain: hormones of hypothalamus |
|pharmacokinetics and pharmacodynamics, features of drugs containing |→ pituitary → hormones of adrenal gland / ovarian. |
|fluoride. Features of corticosteroids dosage, depending on the type of |Correction of prescription on the female and male sex hormones, |
|drug therapy (replacement or pharmacodynamic). |anabolic steroids. |
|Classification of estrogens by origin and chemical structure. |Recommendation for a doctor regarding the interchangeability of sex |
|Pharmacological characteristics of hormones on the basis of estrogens and|hormones with their pharmacodynamics, dosage form side effects. |
|progestogens. The logical relationship between the pharmacological |Consultation for a doctor on the appointment of hormonal |
|effects of estrogens, progestogens and indications for their |contraceptives, depending on age and physiological condition of |
|administration, side effects and contraindications to their use. |women, and dosage form of contraceptive drug. |
|Pharmacological characteristics of of androgenic and anabolic steroids. |Counseling patients on the terms of the rational use of hormonal |
|Pharmacological "face" anti-estrogenic, anti-gestahenic and |contraceptives. |
|anti-androgenic drugs. |Choose from a drug collection drugs for "emergency" contraception, |
|Classification and nomenclature of modern contraceptive drugs. |spermicides, mono-, two- and three-phase combined oral |
|Pharmacological characteristics of hormonal and non-hormonal |contraceptives. |
|contraceptives. Combined oral contraceptives, their comparative |Information for patients on modern medical forms of hormonal |
|characteristics depending on the dose of estrogen and progestin |contraceptives (subcutaneous implants, injectable formulations, depot|
|components. Combined oral estrogen-progestin preparations exhibited |preparations, plasters) and the characteristics of their rational |
|anti-androgenic properties, especially their application. Progestin oral |use. |
|contraceptives, peculiarities of their application. The logical | |
|relationship between side effects and contraindications to the use of | |
|hormonal contraceptives. | |
|Topic 25 |
|Classification and nomenclature of drugs that affect cellular and tissue |Correction of medical prescriptions for drugs that affect cellular |
|metabolism: vitamins, enzyme and anti-enzymes drugs. Pharmacological |and tissue metabolism. Monitoring of dosage of vitamins, enzymes and |
|characteristics of water-soluble and fat-soluble vitamins and |anti-enzymes. |
|anti-enzymes preparations. Features of composition, pharmacodynamics and |Interchangeability enzymes for replacement therapy in diseases of the|
|indications for the use of systemic enzyme therapy. |digestive system, in case of the local treatment of purulent necrotic|
|Classification and pharmacological characteristics of plasma substitutes |processes, scars and spike. |
|and desintoxycants amino acids, preparations for parenteral nutrition, |Consultation a patient on rational use of vitamins, enzymes and |
|correction of acid-base status and ion balance in the body. |anti-enzymes. |
|Classification and pharmacological characteristics of biogenic |Inform a doctor of interchangeability multivitamins and combined |
|stimulants, reparants, antioxidants, and anti-hypoxants, |enzyme preparations, rules of rational use of amino acids, plasma |
|chondroprotectors. The logical relationship between the mechanism of |substitutes, alkali preparations, acids, biogenic stimulants, |
|action, pharmacodynamics and indications for their use. |reparants, chondrotectors, antioxidants and anti-hypoxants. |
|Topic 26 |
|Classification of immunotropic drugs based on chemical structure and |Correction of medical prescriptions for immunotropic drugs. |
|origin. Pharmacological characteristics of immunostimulants. The logical |Choose from a collection of drugs immunostimulants and |
|relationship between the mechanism of action, pharmacodynamics and |immunosuppressants. |
|indications for use immunotropic drugs. Mechanism of action and |Inform the doctor about interchangeability immunotropic drugs based |
|pharmacodynamics of immunosuppressive drugs. Indications for use of |on the presence of branded and generic drugs in the pharmaceutical |
|immunosuppressive drugs in oncology, rheumatology, transplantation, |market. |
|obstetrics. |Advising patients on the rational use of immunostimulants and |
| |immunosuppressants. |
|Topic 27 |
|Basic principles of pharmacotherapy of acute poisoning. The concept of |Correction of medical prescriptions for antidotes. |
|antidotes. |Choose from a collection of drug antidotes for first aid for |
|Classification and pharmacological characteristic of antidotes. Methods |poisoning by muscarine, M-cholinomimetics, PhOS, heavy metal ions, |
|for decontamination and excretion of toxins, that fell through the mouth,|cardiac glycosides, narcotic analgesics, heparin, radioactive |
|skin, mucous membranes. |substances. |
|The concept of forced diuresis, lymph, plasma and enterosorption. | |
|Peculiarities of application of adsorbing, laxatives, vomiting and | |
|diuretic in acute poisoning. | |
|Topic 28 |
|Classification of chemotherapeutic agents. |Correction of medical prescriptions for antiblastomic drugs. |
|Definition of "Antiblastomic drugs." |Consultation to physicians on interchangeability of antiblastomic |
|Classification of antyblastomic drugs according mechanism of action, |preparations, presence of new antiblastomic drugs in the |
|origin. Nomenclature of drugs (international and trade names). |pharmaceutical market. |
|The definition of "cytotoxic" and "cytostatic" effect. |Choose from a collection of submitted drugs antiblastomic of a |
|The requirements to modern antiblastomic drugs. |particular group. Medical advice on the choice of drugs on the |
|Pharmacological characteristic of antiblastomic drugs based on their |correction side effects antiblastomic drugs. |
|mechanism of action, pharmacodynamics, organotropic properties. |Recommendations to physicians regarding interchangeability of |
|Side effects of antiblastomic drugs and means of their correction. |antiblastomic drugs with the peculiarities of their mechanism of |
|Pharmacological characteristic of correctors of side effects of |action and pharmacodynamics. Advising patients on the prevention or |
|antiblastomic drugs. Radioprotectors: group identification, |elimination of side effects of antiblastomic drugs. |
|classification of pharmacological action, duration of radioprotective |Guidelines for physicians and pharmacists on precautions when |
|effect and duration of action. Nomenclature of radioprotectors. Features |handling chemotherapy-radioprotectors and antiblastomic drugs. Choose|
|of the mechanism of action and pharmacological characteristics of various|from a drug collection radioprotectors a group considering different |
|subgroups of radioprotectors. |mechanisms of action. Consultation on interchangeability of |
| |radioprotectors. |
| |Information for patients on the rational use of radioprotectors. |
|Topic 29 |
|The principles of rational antibiotic therapy. |Correction of medical prescriptions for (-lactam antibiotics. |
|Classification of antibiotics in chemical structure, mechanisms of |Consultation a doctor on matters of interchangeability of |
|action, type and range of antimicrobial activity. |penicillins, cephalosporins, carbapenems and monobactams with their |
|Classification of (-lactam antibiotics, mechanism of action, type of |range of action, pharmacokinetics, toxicity, interactions with drugs |
|antimicrobial action. |from other pharmacological groups. |
|Classification, nomenclature and pharmacological characteristics of |Terms of rational use of -(lactam antibiotics as a way to prevent |
|penicillin. Natural penicillins: pharmacokinetic characteristics, |adverse reactions in their application (consultation of the patient).|
|spectrum of antimicrobial action, indications for use. Semisynthetic |Measures to prevent antibiotic resistance. |
|penicillins: features of pharmacodynamics, spectrum antimicrobial action |Choose from a drug collection (-lactam antibiotics. |
|of antistaphylococcal penicillins, aminopenicillins, antipseudomonal |Correction of medical prescriptions for macrolides and azalides. |
|penicillins, indications for their use. |Recommendation to the doctor regarding interchange of macrolides |
|Comparison of amoxicillin and ampicillin for pharmacodynamic and |based of antimicrobial spectrum, pharmacokinetics, efficacy. |
|pharmacokinetic parameters. Comparison of antipseudomonal penicillins. |Consultation the doctor on issues of combined use of macrolides. |
|Inhibitor protected penicillins: pharmacodynamic characteristics, unlike |Correction of medical prescriptions for lincosamides. |
|other drugs in this group. Side effects of antibiotics of the penicillin |Recommendation to the doctor regarding the combined use of |
|group, contraindications to their use. |lincosamides, side effects of this group of antibiotics to prevent or|
|Classification of cephalosporins by generation, spectrum of antimicrobial|reduce the manifestation of possible complications. |
|action. Comparison of cephalosporin of I-IV groups by antimicrobial |Correction of prescriptions for tetracyclines. Recommendations to |
|spectrum, pharmacokinetic properties, indications for use. The logical |doctors and patients in terms of rational use of tetracyclines for |
|connection between the adverse effects of cephalosporins and |the prevention of adverse effects. |
|contraindications to their use. |Correction of medical prescriptions for aminoglycosides. |
|Pharmacological characteristics of carbapenems. Comparison of carbapenem |Recommendation to a doctor to reduce the toxic manifestations in |
|and meropenem for antimicrobial spectrum, antibacterial activity, |using aminoglycosides including dosage, duration of treatment, the |
|toxicity. Features of spectrum of antimicrobial action of monobactames. |patient's age, condition of kidney and liver, etc.. |
|Indications for use monobactamts, side effects and contraindications to |Recommendations to a patient regarding conditions of rational use of |
|their use. |aminoglycosides. |
|Classification of macrolides in chemical structure and method of receipt.|Correction of medical prescriptions for glycopeptides. |
|Pharmacological characteristics of macrolides and azalides. |Recommendations doctors and patients in terms of rational use of |
|Comparison of new macrolides with traditional (peculiarities of |glycopeptides. |
|pharmacokinetics, antibacterial spectrum, efficiency). Interaction of |Correction of medical prescriptions for rifamycins, polypeptide |
|macrolides with other antibiotics and drugs from other pharmacological |antibiotics, oxazolidinones and phosphonates. |
|groups and the possibility of severe complications. |Consultation a doctor and a patient on rational use of rifamycins, |
|The mechanism of action, type and range of antibacterial action, |polypeptide antibiotics, phosphonates, oxazolidinones for the |
|pharmacological characteristics of lincosamides. Side effects |prevention of possible complications in their application. |
|lincosamides and contraindications to their use. Comparison of |Recommendations to the doctor about rational choice of drugs |
|lincosamides with other antibiotics and drugs from other pharmacological|prebiotics and probiotics for prevention and treatment of dysbiosis. |
|groups. | |
|Classification and nomenclature of tetracyclines, mechanism of the | |
|action, type and range of antibacterial action. Features of | |
|pharmacokinetics and indications for use of tetracyclines. Problems of | |
|toxicity and contraindications of tetracyclines. | |
|Classification of aminoglycosides for generations, mechanism of action, | |
|type of antibacterial action. Comparison of aminoglycosides from | |
|different generations in antimicrobial spectrum. Indications for use, | |
|manifestations of toxicity, contraindications to use of aminoglycoside | |
|antibiotics. Factors contributing to the development of side effects of | |
|aminoglycosides. | |
|Synergistic and antagonistic aminoglycosides combination with other | |
|drugs. | |
|Mechanism, type and antibacterial spectrum of chloramphenicols. | |
|Indications, side effects and contraindications to the use of | |
|chloramphenicols. Preparations of chloramphenicols of resorptive and | |
|local application. | |
|Mechanism, type and range of antimicrobial action of glycopeptides. | |
|Indications for use of glycopeptides. Toxic manifestations arising from | |
|the use of glycopeptides, conditions conducive to the development of | |
|these symptoms. | |
|Contraindications to the use of glycopeptides. Comparison of teicoplanin | |
|and vancomycin. | |
|Mechanism, type and range of antimicrobial action of rifamycins. | |
|Indications for use, side effects and contraindications for rifamycins. | |
|Mechanism, type and range of of antimicrobial action of polypeptide | |
|antibiotics: polymyxin B and M sulfate, gramicidin, bacitracin. | |
|Indications, side effects and contraindications to the use of polypeptide| |
|antibiotics. Mechanism and features of antimicrobial spectrum of fuzidin,| |
|indications, side effects and contraindications to its use. | |
|Antibiotics phosphonates, mechanism, type and range of antimicrobial | |
|action. Indications for use fosfomycin, its side effects. | |
|Pharmacological characteristics of oxazolidinone, features of | |
|antimicrobial spectrum. Indications for use of linezolid. | |
|The concept of reserve antibiotics, post antibiotic effect of some groups| |
|of antibiotics. | |
|The concept of dysbiosis and the causes of its development, the possible | |
|ways of of correction of this condition. | |
|The concept of pre-and probiotics, mechanisms of action, features of | |
|microorganisms that are part of probiotics. Pharmacological effects of | |
|pre-and probiotics, indications for their use. | |
|Topic 30 |
|Classification of sulfanilamides. Mechanism of antimicrobial action, |Correction of medical prescriptions for sulfanilamide preparations. |
|determination of bactericidal, bacteriostatic action. Features of |Control of single and daily doses of sulfonamides. |
|pharmacokinetics of sulfonamides. Conditions of rational dose of |Inform a doctor about the interchangeability of of sulfonamides and |
|sulfonamides of various duration (impact, maintenance dose, the |anti-TB drugs. |
|multiplicity of admission). Factors that reduce the risk of side effects |Recommendations to patients on the rational use of of sulfonamides |
|of sulfonamides. The relationship between the indications, side effects |and anti-TB agents. |
|and contraindications to the use of sulfonamides. |Choose from a collection of modern medicine that contain sulfonamides|
|Classification of anti-TB drugs by the mechanism of action and |and anti-TB agents of first and second row. |
|effectiveness. Comparative pharmacological characteristics of drugs of | |
|first and second row. | |
|Topic 31 |
|Classification of antiviral agents. The mechanism of action, indications |Correction of medical prescriptions for antiviral drugs. Choose from |
|and contraindications for use, side effects of drugs for treatment of |a collection of antiviral drugs for the treatment of herpes |
|influenza. Antiherpethetical drugs, mechanism of action, indications, |infections (topical and resorptive), influenza. |
|side effects. Classification of antiretroviral drugs, mechanism of |Inform a doctor for an effective and safe use of antiviral agents. |
|action, indications for use. |Recommendations to patients to prevent side effects of antiviral |
|Comparison of groups of antiretroviral drugs. The main side effects of |drugs. |
|antiretroviral drugs, contraindications to the use. |Features of antiviral agents of topical action. |
|Interferons, classification, pharmacological effects of interferons, |Choose from a collection of interferon drugs that stimulate the |
|indications for use. Side effects of interferons. Inductors of interferon|synthesis of endogenous interferon. |
|synthesis, their classification, pharmacodynamics, indications for use. | |
|Comparison of interferons and their inductors. | |
|Topic 32 |
|Antifungal drugs: pharmacological characteristic of the group, |Correction of medical prescriptions for antifungal drugs. |
|classification of the ways of application, forms of fungal infection. The|Pharmacological and pharmaceutical characteristics of different |
|concept of fungicidal and fungistatic effects of the drugs. |formulations of antifungal agents. |
|The logical relationship between chemical structure, mechanism of action |Consultation a doctor on the rational use of antifungal drugs in |
|and pharmacodynamics of antifungal drugs. Comparison of antifungal drugs |long-term treatment of systemic and localized fungal infections. |
|and their rational use at different location and severity of disease. |Informing the patient about the effective and safe use of antifungal |
|Features of combination therapy with antifungal agents, |agents in the treatment of dermatomycoses, onychomycosis, |
|glucocorticosteroids, antihistamines and anti-bacterial drugs. |trychomycosis. |
|Anthelmintic drugs: classification and pharmacological characteristics of|Correction of medical prescriptions for Anthelmintic drugs. Choose |
|the group. The logical relationship between the mechanism of action of |from a collection of anthelmintic drugs of different groups. |
|drugs, pharmacodynamics and indications for use in nematodoses, |Consultation of a doctor on new and traditional anthelmintic drugs |
|cestodoses, trematodoses and extraintestinal forms of helminthiasis. |represented the pharmaceutical market. Inform the patient on rational|
|Conditions of rational use of anthelmintic drugs and combinations of |use of antigelminthic drugs. |
|drugs of other groups. | |
|Topic 33 |
|Classification, pharmacological characteristics antiprotozoal and |Correction of medical prescriptions for antiprotozoal and |
|antispirochaetic drugs. The concept of asepsis, antisepsis, disinfection |antispirochaetic drugs. |
|and peculiarities in pharmaceutical practice. Factors affecting |Inform a doctor about the interchangeability of drugs according to |
|antiseptic and disinfectant action of drugs. Rules for safe handling with|their pharmacological effects, international nomenclature and trade |
|disinfectants. |names. |
| |Distribution of antiseptics and disinfectants to those used mainly in|
| |surgery, obstetrics, clinical infectious diseases, pathologoanatomic |
| |departments |
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.